Sermorelin

Growth hormone–releasing hormone (GHRH) analog

This page is educational only and is not medical advice. It is not an endorsement to use this compound. See the Educational Disclaimer for details.

Quick Answer

A synthetic 29-amino-acid fragment of human GHRH — one of the earliest GHRH-pathway peptides to reach the market, and the one with the longest FDA-approval history of any compound in this library, even though that approved product is no longer sold.

Why People Are Interested

It's one of the few GHRH-pathway peptides with a real, documented FDA approval history — which makes it a frequent reference point in "is this legal/approved" discussions, even though the specific approved product isn't available anymore and current use is compounded.

What People Hope It May Do

Broader adult hormone-support, recovery, sleep, and body-composition benefits beyond its originally-approved pediatric GH-deficiency indication. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)

Potential / Research Areas

Pituitary function testing in adults and children

Adult growth-hormone-deficiency and aging-related hormone-support protocols (largely off-label, compounded use)

Comparative pharmacology against newer GHRH analogs and secretagogues in this library (tesamorelin, CJC-1295, ipamorelin)

How It May Work

Binds the GHRH receptor on the pituitary gland, stimulating the body's own pulsatile release of growth hormone through the natural feedback pathway, rather than supplying growth hormone directly.

What Human Research Shows

The original FDA approval was supported by clinical trials sufficient to establish safety and effectiveness for its specific approved uses in the 1990s. Since the branded product's discontinuation, most current human use is off-label and compounded, with far less rigorous, non-FDA-reviewed evidence behind that use.

What Preclinical Research Shows

Standard preclinical pharmacology/toxicology package that preceded its original 1990s FDA approval; no meaningful new preclinical program has been run since.

Element Evidence Snapshot™

Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.

Human ResearchModerate
Preclinical ResearchModerate
Clinical Trial ActivityCompleted
Real-World InterestModerate
Regulatory StatusFormerly FDA-Approved / Discontinued (Not Currently Marketed)
Research MomentumLimited

"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.

What People Report

Real-World / Anecdotal Experience — in development. Element Health Labs hasn't yet compiled a reliable synthesis of public anecdotal reports for Sermorelin. When this section is live, it will summarize commonly reported themes from public discussion, clearly separated from the scientific evidence above. Anecdotal reports are not clinical evidence, and individual experiences vary. See Real Experiences for how this is being built.

What Experts Are Saying

Curated commentary specific to Sermorelin is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.

Clinical Trials

For the current, authoritative list of registered trials involving Sermorelin, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.

Potential Risks & Side Effects

General information only — not individualized guidance. The original approved product's labeling covered pituitary/GH-axis effects and injection-site reactions; compounded versions do not carry FDA-reviewed labeling, and quality can vary by pharmacy. Actual use requires a licensed provider.

Regulatory Status

Sermorelin acetate was FDA-approved twice: as Geref (0.05 mg ampules, NDA 19-863, approved December 1990) for evaluating pituitary gland growth-hormone response, and as Geref Diagnostic/therapeutic vials (0.5 mg and 1.0 mg, NDA 20-443, approved September 1997) for treating growth hormone deficiency in children. The manufacturer, EMD Serono, discontinued the product for business reasons in 2008; a 2013 FDA Federal Register determination explicitly found it was not withdrawn for safety or effectiveness reasons. No FDA-approved sermorelin product is currently marketed in the US — all current sermorelin sold is compounded, which means it has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality the way the original approved product was.

What We Still Don't Know

Whether the clinical trial evidence behind the discontinued approved product generalizes to the adult, off-label, compounded use that makes up nearly all current sermorelin use — and what quality variability exists across compounding pharmacies since there's no FDA-reviewed manufacturing standard for the compounded product.

Limitations of Evidence

The strongest evidence (sufficient for two FDA approvals) applies to a product that is no longer manufactured. Current compounded use rests on that older evidence plus off-label clinical experience, not new FDA-reviewed trials in the populations now most commonly using it (adults seeking hormone support, rather than the originally-approved pediatric GH-deficiency population).

Key Takeaway. Sermorelin is a real area of scientific and public interest — but interest, mechanism plausibility, and proof are three different things. As of this review: human research is moderate, preclinical research is moderate, and its regulatory status is Formerly FDA-Approved / Discontinued (Not Currently Marketed). Read the sections above — not just this summary — before forming a view, and talk to a licensed healthcare provider before making any health decision.

Keep Researching

Key Studies

Verified directly against Drugs@FDA primary records, 2026-10-11 (https://www.accessdata.fda.gov/scripts/cder/daf/, Application Numbers 019863 and 020443). NDA 019863 (Geref, sermorelin acetate, 0.05 mg base/amp): applicant EMD Serono, original approval 12/28/1990, for evaluating pituitary somatotroph growth-hormone secretion — confirms this file's "December 1990" date exactly. NDA 020443 (Geref, 0.5 mg and 1.0 mg base/vial): applicant EMD Serono, original approval 09/26/1997 (Type 3 New Dosage Form, orphan status) — confirms this file's "September 1997" date exactly. Both products currently show "Discontinued" marketing status on Drugs@FDA, consistent with the 2013 Federal Register determination below that discontinuation was not for safety/effectiveness reasons.

References

  • FDA Federal Register, "Determination That GEREF (Sermorelin Acetate) Injection... Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness" (2013) — https://www.federalregister.gov/documents/2013/03/04/2013-04827 [re-verified 2026-10-11]
  • FDA Drugs@FDA, NDA 019863 (Geref, sermorelin acetate 0.05 mg base/amp), EMD Serono — approval history record. Verified by direct inspection, 2026-10-11. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863
  • FDA Drugs@FDA, NDA 020443 (Geref, sermorelin acetate 0.5mg/1.0mg base/vial), EMD Serono — approval history record. Verified by direct inspection, 2026-10-11. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443

Last reviewed: 2026-10-11 — Key studies/References independently verified directly against Drugs@FDA primary records (see note above).

Sources. The key studies and references above are our current research notes, including dating/sourcing details where we have them — read each one for its own level of verification rather than treating this list as a uniform claim. This page will not publish claims backed by unverified or fabricated citations.
Last reviewed: 2026-10-11 — Key studies/References independently verified directly against Drugs@FDA primary records (see note above).